37412-64-9

Basic information

• Product Name: 1-(4-METHOXYBENZYL)-2-THIOUREA
• Synonyms: 1-(4-METHOXYBENZYL)-2-THIOUREA
• CAS NO: 37412-64-9
• Molecular Formula: C₉H₁₂N₂OS
• Molecular Weight: 196.27
• Mol File: 37412-64-9.mol
• Article Data: 8

Chemical Properties

• Melting Point: 135 °C
• Boiling Point: 344.5 °C at 760 mmHg
• Flash Point: 162.1 °C
• Appearance: /
• Density: 1.198 g/cm³
• Vapor Pressure: 6.58E-05mmHg at 25°C
• Refractive Index: 1.611
• CAS DataBase Reference: 1-(4-METHOXYBENZYL)-2-THIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-METHOXYBENZYL)-2-THIOUREA(37412-64-9)
• EPA Substance Registry System: 1-(4-METHOXYBENZYL)-2-THIOUREA(37412-64-9)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 37412-64-9(Hazardous Substances Data)

Usage

Description

1-(4-METHOXYBENZYL)-2-THIOUREA, with the molecular formula C10H13NOS, is an organic compound characterized by the presence of a benzyl group substituted with a methoxy group and a thiourea group. It is recognized for its potential applications in medicinal chemistry due to its diverse biological activities, including antidiabetic, anticancer, and anti-inflammatory properties. Additionally, it holds promise as a reagent in organic synthesis and as a building block for the preparation of other chemical compounds, making it a subject of interest in the fields of pharmaceutical and industrial applications.

Uses

Used in Pharmaceutical Industry:
1-(4-METHOXYBENZYL)-2-THIOUREA is used as a pharmaceutical agent for its antidiabetic properties, helping to manage blood sugar levels and potentially contributing to the development of new treatments for diabetes.
1-(4-METHOXYBENZYL)-2-THIOUREA is used as an anticancer agent, leveraging its ability to target and inhibit the growth of cancer cells, making it a candidate for further research and development in oncology.
1-(4-METHOXYBENZYL)-2-THIOUREA is used as an anti-inflammatory agent, potentially aiding in the reduction of inflammation and associated symptoms, which could be beneficial in the treatment of various inflammatory conditions.
Used in Organic Synthesis:
1-(4-METHOXYBENZYL)-2-THIOUREA is used as a reagent in organic synthesis, facilitating the creation of new chemical compounds and contributing to the advancement of chemical research and development.
Used in Chemical Compound Preparation:
1-(4-METHOXYBENZYL)-2-THIOUREA is used as a building block in the preparation of other chemical compounds, indicating its utility in the synthesis of complex molecules for various applications across different industries.

InChI:InChI=1/C9H12N2OS/c1-12-8-4-2-7(3-5-8)6-11-9(10)13/h2-5H,6H2,1H3,(H3,10,11,13)

Upstream product

• 1147550-11-5 ammonium thiocyanate 
• 566163-51-7 N-((4-methoxybenzyl)carbamothioyl)benzamide 
• 1336-21-6 ammonium hydroxide 
• 88681-68-9 di(1H-imidazol-2-yl)methanethione 
• 2393-23-9 4-methoxy-benzylamine 
• 3694-57-3 1-(isothiocyanatomethyl)-4-methoxybenzene 
• 244032-72-2 [1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-thiourea 

Downstream Products

• 384858-14-4 N-[(4-methoxyphenyl)methyl]thiazole 2-amine 
• 1353585-44-0 C₂₁H₁₉N₅O₃S₂ 
• 1353585-37-1 3-[2-(4-fluoro-phenoxy)-ethyl]-1-(4-methoxy-benzyl)-6-methylsulfanyl-1H-[1,3,5]triazine-2,4-dione 
• 1353585-35-9 3-(2,3-dihydro-benzofuran-5-ylmethyl)-1-(4-methoxy-benzyl)-6-methylsulfanyl-1H-[1,3,5]triazine-2,4-dione 
• 910114-60-2 1-(4-methoxy-benzyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)dione 
• 910114-73-7 6-(2-amino-ethylamino)-1-(4-methoxy-benzyl)-3-(4-nitro-benzyl)-1H-[1,3,5]triazine-2,4-dione 
• 910114-72-6 1-(4-methoxy-benzyl)-6-methylsulfanyl-3-(4-nitro-benzyl)-1H-[1,3,5]triazine-2,4-dione 
• 910114-62-4 6-(2-aminoethylamino)-3-(4-ethylbenzyl)-1-(4-methoxybenzyl)-1,3,5-triazine-2,4(1H,3H)-dione 
• 910114-61-3 3-(4-ethylbenzyl)-1-(4-methoxybenzyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)-dione 
• 871300-47-9 1-(4-methoxy-benzyl)-2-methyl-3-thiopseudourea 
• 1364930-40-4 1-[2-(4-methoxy-benzylamino)-4-methyl-thiazol-5-yl]-ethanone 
• 553-13-9 Zolamine 

Relevant articles and documents

Synthesis of monosubstituted thioureas by vapour digestion and mechanochemical amination of thiocarbamoyl benzotriazoles

Thiocarbamoyl benzotriazoles, as safe and easy-to-handle isothiocyanate equivalents, were quantitatively converted to N-monosubstituted thioureas by vapour digestion synthesis under an ammonia atmosphere. This simple, but timely process provided a synthetic platform that enabled the "slow" amination reaction to be successfully transformed into a rapid one aided by mechanochemical milling. The ammonium chloride/sodium carbonate equimolar mixture allowed in situ formation of ammonia under ball-milling conditions. This novel and green approach yielded aromatic and aliphatic primary thioureas in near-quantitative isolated yields with workup entirely based on using only water. In addition, the molecular and crystal structures of selected polyaromatic primary thioureas were determined from the synchrotron powder diffraction data.

Clobenpropit analogs as dual activity ligands for the histamine H3 and H4 receptors: Synthesis, pharmacological evaluation, and cross-target QSAR studies

Previous studies have demonstrated that clobenpropit (N-(4-chlorobenzyl)-S-[3-(4(5)-imidazolyl)propyl]isothiourea) binds to both the human histamine H3 receptor (H3R) and H4 receptor (H4R). In this paper, we describe the synthesis and pharmacological characterization of a series of clobenpropit analogs, which vary in the functional group adjacent to the isothiourea moiety in order to study structural requirements for H3R and H4R ligands. The compounds show moderate to high affinity for both the human H3R and H4R. Furthermore, the changes in the functional group attached to the isothiourea moiety modulate the intrinsic activity of the ligands at the H4R, ranging from neutral antagonism to full agonism. QSAR models have been generated in order to explain the H3R and H4R affinities.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.